ORIGINAL ARTICLES
Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study

https://doi.org/10.1016/S1081-1206(10)61430-5Get rights and content

Background

For patients whose asthma is uncontrolled with low-dose inhaled corticosteroids, addition of alternative therapy instead of increasing the steroid dose is recommended by current treatment guidelines.

Objective

To compare montelukast, a oncedaily leukotriene receptor antagonist, and salmeterol, a twice-daily, long-acting β-agonist, concomitantly administered with inhaled fluticasone, according to the percentage of patients without an asthma attack for 1 year.

Methods

A randomized, doubleblind, double-dummy, multicenter study was conducted. Adult patients with moderate-to-severe persistent asthma (ages 14-73 years) receiving inhaled fluticasone (220 μg/d) who remained symptomatic during a 4-week run-in period were randomized to the addition of salmeterol (84 μg/d) or montelukast (10 mg/d) for 48 weeks.

Results

Of the 1,473 randomized patients, 743 were randomized to montelukast and 730 to salmeterol; 1,059 patients completed the study. Eighty percent of patients in the montelukast group and 83.3% of patients in the salmeterol group remained attack free during the 48 weeks of treatment (relative risk, 1.20; 95% confidence interval, 0.96-1.49). Montelukast significantly reduced blood eosinophil counts compared with salmeterol, whereas salmeterol significantly increased prealbuterol forced expiratory volume in 1 second, asthma-specific quality of life, morning peak expiratory flow rate, and decreased nocturnal awakenings compared with montelukast. Differences between treatments were small, and both treatments were generally well tolerated.

Conclusions

Addition of montelukast or salmeterol to an inhaled corticosteroid similarly protected most patients from experiencing an asthma attack during a 1-year period, but, based on noninferiority limits, the study was inconclusive with regard to a difference between treatment groups.

REFERENCES (38)

  • MR Sears

    Deleterious effects of inhaled β-agonists: short-acting and long-acting agents differ

    Chest

    (2001)
  • National Asthma Education and Prevention Program

    Guidelines for the diagnosis and management of asthma: update on selected topics-2002 [Expert Panel Report]

    Environ Int

    (2002)
  • National Institutes of Health and National Heart Lung and Blood Institute. Global Initiative for Asthma: Pocket Guide...
  • BJ Lipworth

    Systemic adverse effects of inhaled corticosteroid therapy

    Arch Intern Med

    (1999)
  • A Woolcock et al.

    Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

    Am J Respir Crit Care Med

    (1996)
  • RA Pauwels et al.

    Effect of inhaled formoterol and budesonide on exacerbations of asthma

    N Engl J Med

    (1997)
  • H Bisgaard

    Effect of long-acting β2 agonists on exacerbation rates of asthma in children

    Pediatr Pulmonol

    (2003)
  • KV Blake

    Montelukast: data from clinical trials in the management of asthma

    Ann Pharmacother

    (1999)
  • K Malmstrom et al.

    Montelukast (MK-0476), a leukotriene receptor antagonist provides additional clinical benefit to chronic asthmatic patients using inhaled beclomethasone

    Eur Respir J

    (1998)
  • Cited by (55)

    • Antileukotriene Therapy in Asthma

      2014, Middleton's Allergy: Principles and Practice: Eighth Edition
    • Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 μg/Salmeterol 50 μg

      2009, Pulmonary Pharmacology and Therapeutics
      Citation Excerpt :

      However, clinical evidence to date strongly favors inhaled corticosteroids over cysteinyl leukotriene antagonists in the treatment of intermittent or mild persistent asthma with little benefit of combining the two [16,38,39]. In moderate to severe persistent asthma, there is greater clinical benefit, especially improved lung function, when combining ICS with a LABA compared to combining ICS with an anti-leukotriene agent [40–44]. In moderate to severe asthmatics already on ICS and LABA, the addition of montelukast or zileuton has not been well evaluated.

    • Patient-Centered Care for Childhood Asthma

      2009, Journal for Nurse Practitioners
    View all citing articles on Scopus

    This study was supported by Merck & Co Inc.

    View full text